Eli Lilly will announce Q4 2024 results, with analysts estimating $13.7 billion in sales and $4.94 EPS, alongside a revenue growth outlook for 2024.

Eli Lilly (LLY) is set to announce Q4 earnings results, with analysts expecting positive growth driven by key drugs and new product launches.

Robert F. Kennedy Jr.’s HHS nomination moves to a full Senate vote; Donald Trump’s tariff war sparks China-related concerns for biopharma; Pfizer, Merck and more announce Q4 and 2024 earnings; and the ...

Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...

The S&P 500 index trades at a forward price/earnings ratio of 21.9. The U.S. large-cap benchmark stock index is weighted by market capitalization. The index's current forward P/E valuation is 18% ...

Novo Nordisk forecasts 2025 sales growth will slow, citing increased competition for its obesity drug Wegovy and aligning ...

Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.

Amid growing concern of the overuse and misuse of obesity drugs, the UK’s pharmacies regulator rolled out stricter guidelines ...

Alzheimer’s disease has afflicted Hannah Richardson’s family for generations. A rare genetic mutation, passed down from her great-grandmother, has struck her relatives with the first signs of memory ...

Aktis Oncology, an oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for ...

John Lilly and the Earth Coincidence Control Office’ from Michael Almereyda and Courtney Stephens, narrated by Chloë Sevigny, debuts at Rotterdam, exploring the life of the utopian neuroscientist.